FDA Commissioner Kessler tells Senate committee that reform bill may lengthen reviews.
This article was originally published in The Tan Sheet
Executive Summary
SENATE FDA REFORM BILL DEADLINES COULD LENGTHEN PRODUCT REVIEWS, FDA Commissioner David Kessler predicted during testimony at a Feb. 21 hearing before Sen. Nancy Kassebaum's (R-Kans.) Labor & Human Resources Committee. "I think what will happen is that if everyone is held to that very, very short timeframe for all drugs, if there are problems with the application, the applications are going to get turned down," he said.